AR074055A1 - Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo - Google Patents
Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodoInfo
- Publication number
- AR074055A1 AR074055A1 ARP090104083A ARP090104083A AR074055A1 AR 074055 A1 AR074055 A1 AR 074055A1 AR P090104083 A ARP090104083 A AR P090104083A AR P090104083 A ARP090104083 A AR P090104083A AR 074055 A1 AR074055 A1 AR 074055A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- vector
- polynucleotide
- sequence
- polypeptide
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 6
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 title 1
- 241000283073 Equus caballus Species 0.000 title 1
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 title 1
- 208000012860 Horse disease Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 abstract 10
- 102000040430 polynucleotide Human genes 0.000 abstract 10
- 108091033319 polynucleotide Proteins 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000013604 expression vector Substances 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 241000120516 African horse sickness virus Species 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10807508P | 2008-10-24 | 2008-10-24 | |
| US16351709P | 2009-03-26 | 2009-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074055A1 true AR074055A1 (es) | 2010-12-22 |
Family
ID=41818403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104083A AR074055A1 (es) | 2008-10-24 | 2009-10-23 | Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8168200B2 (OSRAM) |
| EP (1) | EP2358742B1 (OSRAM) |
| JP (1) | JP2012506699A (OSRAM) |
| KR (1) | KR101719005B1 (OSRAM) |
| CN (1) | CN102245627A (OSRAM) |
| AP (1) | AP3334A (OSRAM) |
| AR (1) | AR074055A1 (OSRAM) |
| AU (1) | AU2009308331C1 (OSRAM) |
| BR (2) | BRPI0920622B1 (OSRAM) |
| CA (1) | CA2741333C (OSRAM) |
| CL (1) | CL2011000922A1 (OSRAM) |
| EA (1) | EA024111B1 (OSRAM) |
| ES (1) | ES2681693T3 (OSRAM) |
| MX (1) | MX2011004219A (OSRAM) |
| NZ (2) | NZ592388A (OSRAM) |
| PL (1) | PL2358742T3 (OSRAM) |
| PT (1) | PT2358742T (OSRAM) |
| WO (1) | WO2010048394A2 (OSRAM) |
| ZA (1) | ZA201103031B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0920622B1 (pt) * | 2008-10-24 | 2019-11-12 | Merial, Inc. | vacina contra o vírus da doença equina africana |
| JP6260972B2 (ja) | 2012-02-14 | 2018-01-17 | メリアル インコーポレイテッド | 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン |
| EP3149158B1 (en) * | 2014-11-04 | 2017-10-11 | Deltamune (PTY) Limited | Live attenuated african horsesickness virus |
| US10334248B2 (en) * | 2015-05-29 | 2019-06-25 | Qualcomm Incorporated | Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design |
| CN111867637B (zh) * | 2018-03-19 | 2024-05-03 | 勃林格殷格翰动物保健有限公司 | 新ehv插入位点ul43 |
| CN116041447A (zh) * | 2022-12-29 | 2023-05-02 | 北京亿森宝生物科技有限公司 | 一种检测非洲马瘟病毒的试剂盒及其应用 |
| CN116656731B (zh) * | 2023-05-25 | 2024-04-12 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法 |
| WO2025013146A1 (ja) | 2023-07-07 | 2025-01-16 | 中京油脂株式会社 | 分散体 |
| CN117737310B (zh) * | 2024-01-26 | 2024-07-16 | 中国农业科学院北京畜牧兽医研究所 | 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| ZA976424B (en) * | 1996-07-05 | 1999-01-22 | Agricultural Research Council | Nucleic acid sequences coding for african horsesickness virus outer capsid components |
| FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
| US7862821B2 (en) * | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| BRPI0920622B1 (pt) * | 2008-10-24 | 2019-11-12 | Merial, Inc. | vacina contra o vírus da doença equina africana |
-
2009
- 2009-10-22 BR BRPI0920622-1A patent/BRPI0920622B1/pt active IP Right Grant
- 2009-10-22 NZ NZ592388A patent/NZ592388A/en unknown
- 2009-10-22 EA EA201100674A patent/EA024111B1/ru unknown
- 2009-10-22 PL PL09760655T patent/PL2358742T3/pl unknown
- 2009-10-22 CA CA2741333A patent/CA2741333C/en active Active
- 2009-10-22 MX MX2011004219A patent/MX2011004219A/es active IP Right Grant
- 2009-10-22 KR KR1020117011832A patent/KR101719005B1/ko active Active
- 2009-10-22 CN CN2009801492091A patent/CN102245627A/zh active Pending
- 2009-10-22 PT PT97606552T patent/PT2358742T/pt unknown
- 2009-10-22 ES ES09760655.2T patent/ES2681693T3/es active Active
- 2009-10-22 BR BR122019001455-8A patent/BR122019001455B1/pt active IP Right Grant
- 2009-10-22 WO PCT/US2009/061669 patent/WO2010048394A2/en not_active Ceased
- 2009-10-22 AU AU2009308331A patent/AU2009308331C1/en active Active
- 2009-10-22 NZ NZ598605A patent/NZ598605A/en unknown
- 2009-10-22 EP EP09760655.2A patent/EP2358742B1/en active Active
- 2009-10-22 JP JP2011533331A patent/JP2012506699A/ja active Pending
- 2009-10-22 US US12/604,048 patent/US8168200B2/en active Active
- 2009-10-22 AP AP2011005954A patent/AP3334A/xx active
- 2009-10-23 AR ARP090104083A patent/AR074055A1/es active IP Right Grant
-
2011
- 2011-04-21 ZA ZA2011/03031A patent/ZA201103031B/en unknown
- 2011-04-21 CL CL2011000922A patent/CL2011000922A1/es unknown
-
2012
- 2012-01-25 US US13/357,755 patent/US20120114691A1/en not_active Abandoned
-
2013
- 2013-10-22 US US14/060,023 patent/US20140120133A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074055A1 (es) | Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR065075A1 (es) | Vectores para la expresion multiple de genes | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| MX337417B (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores. | |
| CL2021000549A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) | |
| AR083848A1 (es) | Polipeptidos con actividad de fosfolipasa c y polinucleotidos que los codifican | |
| AR067972A1 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| ES2676542T3 (es) | Composiciones de CDV recombinante y usos de las mismas | |
| CL2020002373A1 (es) | Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422). | |
| JP2012506699A5 (OSRAM) | ||
| EP4353256A3 (en) | Induction of cross-reactive cellular response against rhinovirus antigens | |
| AR071534A1 (es) | Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa | |
| DK200601181A (da) | Fiskevaccine | |
| CO2022001782A2 (es) | Vacuna contra la peste porcina africana | |
| ES2663242T3 (es) | Productos génicos expresados de forma diferencial en tumores y su utilización | |
| AR071696A1 (es) | Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos. | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |